Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes|
- Identify genes whose mutations cause Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis. [ Time Frame: Weekly ] [ Designated as safety issue: No ]
- To determine if there are proteins expressed by cells from patients that might be targets for the immune response. [ Time Frame: Weekly ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||July 2006|
|Estimated Study Completion Date:||July 2020|
|Estimated Primary Completion Date:||July 2020 (Final data collection date for primary outcome measure)|
Patients suspected to have one of the following blood disorders: polycythemia vera, myelofibrosis or essential thrombocythemia.
Healthy Female Controls
Healthy females who do not have the blood disorders; Polycythemia Vera, Essential Thrombocythemia and/or Myelofibrosis.
Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF), also known as the Philadelphia Chromosome negative myeloproliferative disorders (MPDs), are not congenital, but acquired. The purpose of this project is to find genes whose mutations cause these disorders, as well as improve diagnostic measures for these diseases. When this is accomplished new therapies to control and eventually cure the disease can be designed.
All subjects will be asked to donate 4-6 teaspoons of blood. On occasion, if the blood cells from a particular sample do not grow well and the DNA from that sample is used up or other tests are needed, we may ask to collect additional samples. In patients who have undergone a bone marrow biopsy as part of their clinical evaluation, we will test the reproducibility between pathologists for the revised 2008 WHO diagnostic criteria to diagnose myeloproliferative disorders (MPD).
Please refer to this study by its ClinicalTrials.gov identifier: NCT00715247
|Contact: Josef T Prchal, MDfirstname.lastname@example.org|
|Contact: Kim Hickman, BSemail@example.com|
|United States, Utah|
|University of Utah||Recruiting|
|Salt Lake City, Utah, United States, 84132|
|Contact: Josef T Prchal, MD 801-581-4220 firstname.lastname@example.org|
|Contact: Kim Hickman, BS 801-581-3707 email@example.com|
|Sub-Investigator: Neeraj Agarwal, MD|
|Sub-Investigator: Mohamed Salama, MD|
|Sub-Investigator: Archana Agarwal, MD|
|Sub-Investigator: Todd Kelley, MD|
|Sub-Investigator: Maurizio Zangari, MD|
|Sub-Investigator: Michael Deininger, MD|
|Sub-Investigator: Sabina Swierczek, PhD|
|Principal Investigator:||Josef T Prchal, MD||University of Utah|